Japan Lifeline is a prominent company within the medical device industry, and as a manufacturer has been
delivering high-quality products to meet the clinical needs for more than 20 years. The company continuously
conducts research to improve its technologies with the hopes of striving to improve the quality of care.
Japan Lifeline was established in 1981 and started as a distributor of cardiac pacemakers in Japan. As
the business grew, there was a need to establish its own manufacturing in order to fulfil the unmet needs of
the medical device industry.
In 1999, the research center for R&D was established to start developing
products such as coronary guidewires and cardiac ablation catheters. In the following year, its first own
manufacturing facility was established in Ukima, Tokyo. Japan Lifeline had great early success in the
cardiac ablation market with nearly 50% of the market share selling its ablation catheter, the Ablaze
series.
In 2009, Japan Lifeline conducted a clinical trial with 140 patients for the atrial
cardioversion system, Shock AT, which was approved in 2012. Since then, it has been a great success and well
received by the Japanese electrophysiology market resulting in over 80% of the market share.
To increase
the manufacturing capacity in order to meet the market demands, the Toda Factory was opened in 2012, and it
has been the main factory for cardiac ablation catheter manufacturing.
Along with the growth of the electrophysiology business, Japan Lifeline also achieved business growth in the vascular surgery field. In 2011, the Ichihara Factory was established to develop open stent grafts, which were introduced to the market in 2014 with a great success.
To ensure top-level quality, the Oyama Factory was established in 2014, which is responsible for the final
processes such as inspection, packaging, and sterilization for both cardiac ablation and diagnostic
catheters. The addition of the Oyama Factory, allowed Japan Lifeline to satisfy the increasing demands of
the market while maintaining high-quality standards.
In order to fulfill the growing production and
control the manufacturing cost, Japan Lifeline built the Malaysia Factory, which is its first own factory
outside of Japan, in 2020. With its complete manufacturing capability and top-quality standards, Japan
Lifeline continues to improve and expand its product portfolio for the comfort of patients worldwide.
With its success in the medical industry over 40 years, the company marked its success by listing in the JASDAQ in 1997 and now found further success by moving up to the Tokyo Stock Exchange Prime Market (ticker: 7575).
JLL Corporate WebsiteJapan Lifeline aims to achieve sustainable growth as a company by building better relationships with our diverse stakeholders and working to solve environmental and social issues.
For inquiries, please fill out the inquiry form.
